Drug Approval | May 15, 2022
USFDA approves novel, dual-targeted treatment for type 2 diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
In clinical trials, treatment proved more effective than other therapies evaluated
India has the second-largest number of adults with diabetes globally, after China
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)